Association of antidepressant and atypical antipsychotic use with cardiovascular events and mortality in a veteran population

Pharmacotherapy

Volumn 33, Issue 10, 2013, Pages 1053-1061

  Acharya, Tushar ^a,b   Acharya, Sabeena ^b   Tringali, Steven ^a,b   Huang, Jian ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antidepressant; atypical antipsychotics; cardiovascular; mortality

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIRTAZAPINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG USE; FEMALE; FRAMINGHAM RISK SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; VETERAN;

ANTIDEPRESSANT; ATYPICAL ANTIPSYCHOTICS; CARDIOVASCULAR; MORTALITY;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; VETERANS;

EID: 84900864696     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1311     Document Type: Article

References (39)

1. Wulsin LR, Vaillant GE, Wells VE,. A systematic review of the mortality of depression. Psychosom Med 1999; 61: 6-17.
2. Black DW, Carney CP, Forman-Hoffman VL, et al. Depression in veterans of the first gulf war and comparable military controls. Ann Clin Psychiatry 2004; 16: 53-61.
3. Helzer JE, Robins LN, Wish E, Hesselbrock M,. Depression in Viet Nam veterans and civilian controls. Am J Psychiatry 1979; 136: 4B.
4. Burt C, Schappert S,. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999-2000. National Center for Health Statistics. Vital Health Stat 13 2004; 157: 1-70.
5. Rumsfeld JS, Ho M,. Depression and cardiovascular disease a call for recognition. Circulation 2005; 111: 250-3.
6. Glassman A,. Depression and cardiovascular disease. Pharmacopsychiatry 2008; 41: 221-5.
7. Musselman DL, Evans DL, Nemeroff CB,. The relationship of depression to cardiovascular disease epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580-92.
8. Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans: Cardiovascular Health Study Collaborative Research Group. Circulation 2000; 102: 1773-9.
9. Frasure-Smith N, Lesperance F, Talajic M,. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270: 1819-25.
10. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161: 1849-56.
11. Bush DE,. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001; 88: 337-41.
12. Writing Committee for the ENRICHD Investigators. The effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA 2003; 289: 3106-16.
13. CREATE Investigators [Lespérance F]. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-79.
14. Glassman AH, Bigger JT Jr,. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1981; 38: 815-20.
15. Cohen HW, Gibson G, Alderman MH,. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108: 2-8.
16. Sauer WH, Berlin JA, Kimmel SE,. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-8.
17. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: Sertraline antidepressant heart attack randomized trial. JAMA 2002; 288: 701-9.
18. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2010; 363: 1092-3.
19. Alberti KG, Zimmet P, Shaw J,. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
20. Casey DE,. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005; 118: 15-22.
21. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW,. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
22. Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42.
23. Helmeste DM, Tang SW, Reist C, et al. Serotonin uptake inhibitors modulate intracellular Ca2 + mobilization in platelets. Eur J Pharmacol 1995; 288: 373-7.
24. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-44.
25. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J,. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358-67.
26. Schneider LS, Dagerman KS, Insel P,. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43.
27. Ray WA, Chung CP, Murray KT, Hall K, Stein CM,. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35.
28. Ruschena D, Mullen PE, Palmer S, et al. Choking deaths: the role of antipsychotic medication. Br J Psychiatry 2003; 183: 446-50.
29. Zornberg GL, Jick H,. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-23.
30. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445.
31. Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66: 1090-6.
32. Douglas IJ, Smeeth L,. Exposure to antipsychotics and risk of stroke: self-controlled case series study. BMJ 2008; 337: a1227.
33. Montgomery SA,. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 (Suppl 4): 37-45.
34. Watson K, Summers KM,. Depression in patients with heart failure: clinical implications and management. Pharmacotherapy 2009; 29 (1): 49-63.
35. Fawcett J, Barkin R,. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267-85.
36. Leonard C, Bilker W, Newcomb C, et al. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011; 20 (9): 903-13.
37. van Melle J, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007; 190: 460-6.
38. Honig A, Kuyper A, Schene A, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 2007; 69: 606-13.
39. de Jonge P, Honig A, van Melle J, et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry 2007; 164: 1371-8.